Cargando…
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors
Epidermal Growth Factor Receptor (EGFR) activates a robust signalling network to which colon cancer tumours often become addicted. Cetuximab, one of the monoclonal antibodies targeting this pathway, is employed to treat patients with colorectal cancer. However, many patients are intrinsically refrac...
Autores principales: | Gelfo, Valerio, Rodia, Maria Teresa, Pucci, Michela, Dall'Ora, Massimiliano, Santi, Spartaco, Solmi, Rossella, Roth, Lee, Lindzen, Moshit, Bonafè, Massimiliano, Bertotti, Andrea, Caramelli, Elisabetta, Lollini, Pier-Luigi, Trusolino, Livio, Yarden, Yosef, D'Uva, Gabriele, Lauriola, Mattia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342152/ https://www.ncbi.nlm.nih.gov/pubmed/27708224 http://dx.doi.org/10.18632/oncotarget.12354 |
Ejemplares similares
-
A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy
por: Gelfo, Valerio, et al.
Publicado: (2018) -
Glucocorticoid Receptor Modulates EGFR Feedback upon Acquisition of Resistance to Monoclonal Antibodies
por: Gelfo, Valerio, et al.
Publicado: (2019) -
Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment
por: Lauriola, Mattia, et al.
Publicado: (2014) -
Beta-Catenin/HuR Post-Transcriptional Machinery Governs Cancer Stem Cell Features in Response to Hypoxia
por: D’Uva, Gabriele, et al.
Publicado: (2013) -
Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma
por: Hedegger, Kathrin, et al.
Publicado: (2023)